• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Dashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlerts
    Company
    AboutQuantisnow PlusContactJobs
    Legal
    Terms of usePrivacy policyCookie policy

    November 9, 2023 - FDA Approves First Treatment for Patients with Rare Inherited Blood Clotting Disorder

    11/9/23 2:30:20 PM ET
    $SRAX
    $SNAP
    Advertising
    Consumer Discretionary
    Computer Software: Programming Data Processing
    Technology
    Get the next $SRAX alert in real time by email
    For Immediate Release:
    November 09, 2023

    Today, the U.S. Food and Drug Administration approved Adzynma, the first recombinant (genetically engineered) protein product indicated for prophylactic (preventive) or on demand enzyme replacement therapy (ERT) in adult and pediatric patients with congenital thrombotic thrombocytopenic purpura (cTTP), a rare and life-threatening blood clotting disorder.

    “The FDA remains deeply committed in our efforts to help facilitate the development and approval of safe and effective therapies for patients with rare diseases,” said Peter Marks, M.D., Ph.D., director of the FDA’s Center for Biologics Evaluation and Research. “Without treatment, cTTP is ultimately fatal. Today’s approval reflects important progress in the development of much-needed treatment options for patients affected by this life-threatening disorder.”

    The very rare, inherited blood clotting disorder called cTTP is caused by a disease-causing mutation in the ADAMTS13 gene, which is responsible for making an enzyme, also named ADAMTS13, that regulates blood clotting. A deficiency in this enzyme causes blood clots to form in the small blood vessels throughout the body. It is estimated that cTTP affects fewer than one thousand people in the United States. Symptoms typically develop in infancy or early childhood, but in some cases may develop in adulthood and may first manifest during pregnancy. Individuals with cTTP may experience severe bleeding episodes, strokes and damage to vital organs. If left untreated, the disease can be fatal. Treatment for cTTP typically involves prophylactic plasma-based therapy for individuals with chronic disease to reduce the risk of clotting/bleeding by replenishing the absent/low ADAMTS13 enzyme.

    Adzynma is a purified recombinant form of the ADAMTS13 enzyme that works by providing a replacement for the low levels of the deficient enzyme in patients with cTTP. For prophylactic ERT, Adyznma is administered to help reduce the risk of disease symptoms. The product may also be administered as an on-demand ERT for treatment when the patient is experiencing an acute event. Adzynma is administered intravenously once every other week for prophylactic ERT, and once daily for on-demand ERT. 

    The safety and effectiveness of Adzynma were demonstrated in a global study evaluating prophylactic and on-demand ERT with Adzynma compared to plasma-based therapies in patients with cTTP.

    The efficacy of Adzynma in the prophylactic treatment of patients with cTTP was evaluated in 46 patients who were randomized to receive 6 months of treatment with either Adzynma or plasma based therapies (Period 1), then crossed over to the other treatment for 6 months (Period 2). The efficacy was demonstrated based on the incidence of thrombotic thrombocytopenic purpura (TTP) events, and TTP manifestations, as well as the incidence of the need for supplemental doses. 

    The efficacy of on demand ERT was evaluated based on the proportion of acute TTP events responding to Adzynma in both the prophylactic and the on-demand cohorts throughout the duration of the study. All acute and subacute TTP events resolved after treatment with either Adzynma or plasma based therapies. 

    The most common side effects associated with Adzynma include headache, diarrhea, migraine, abdominal pain, nausea, upper respiratory tract infection, dizziness and vomiting. During the clinical studies, no adverse events, including allergic reactions, were observed during the administration of Adzynma.

    The application was awarded a Rare Pediatric Disease Priority Review Voucher, and granted Priority Review, Fast Track and Orphan designations.

    The FDA granted approval of Adzynma to Takeda Pharmaceuticals U.S.A. Inc.

    ###

    Boilerplate

    The FDA, an agency within the U.S. Department of Health and Human Services, protects the public health by assuring the safety, effectiveness, and security of human and veterinary drugs, vaccines and other biological products for human use, and medical devices. The agency also is responsible for the safety and security of our nation’s food supply, cosmetics, dietary supplements, radiation-emitting electronic products, and for regulating tobacco products.


    Inquiries

    Media:
    Carly (Kempler) Pflaum
    240-672-8872
    Consumer:
    888-INFO-FDA

     
    Get the next $SRAX alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $SRAX
    $SNAP

    CompanyDatePrice TargetRatingAnalyst
    Snap Inc.
    $SNAP
    2/11/2025Buy → Neutral
    Guggenheim
    Snap Inc.
    $SNAP
    2/5/2025Overweight
    Barclays
    Snap Inc.
    $SNAP
    2/5/2025$15.00 → $11.00Overweight → Equal Weight
    Wells Fargo
    Snap Inc.
    $SNAP
    10/23/2024$17.00Mkt Perform → Mkt Outperform
    JMP Securities
    Snap Inc.
    $SNAP
    9/20/2024$11.00Neutral
    B. Riley Securities
    Snap Inc.
    $SNAP
    9/5/2024$8.00Neutral
    Cantor Fitzgerald
    Snap Inc.
    $SNAP
    8/2/2024Buy → Hold
    HSBC Securities
    Snap Inc.
    $SNAP
    7/23/2024$12.00 → $16.00Underweight → Equal-Weight
    Morgan Stanley
    More analyst ratings

    $SRAX
    $SNAP
    Financials

    Live finance-specific insights

    See more
    • Snap Inc. Announces First Quarter 2025 Financial Results

      First quarter revenue increased 14% year-over-year to $1,363 million Daily Active Users increased 9% year-over-year to 460 million Net loss improved 54% year-over-year to $140 million Adjusted EBITDA improved 137% year-over-year to $108 million Snap Inc. (NYSE:SNAP) today announced financial results for the quarter ended March 31, 2025. "We surpassed an important milestone in Q1, with our community growing to over 900 million monthly active users," said Evan Spiegel, CEO. "Quarterly revenue increased 14% year-over-year, driven by the progress we have made with our direct-response advertising solutions, continued momentum in driving performance for small and medium sized businesses, and

      4/29/25 4:10:00 PM ET
      $SNAP
      Computer Software: Programming Data Processing
      Technology
    • Snap Inc. Announces Date of First Quarter 2025 Results Conference Call

      Snap Inc. (NYSE:SNAP) will hold its quarterly conference call to discuss first quarter 2025 financial results on Tuesday, April 29, 2025 at 2:00 p.m. Pacific Time (5:00 p.m. Eastern Time). A live webcast and replay of the conference call will be accessible on Snap Inc.'s Investor Relations website for at least 90 days at: http://investor.snap.com. About Snap Inc. Snap Inc. is a technology company. We believe the camera presents the greatest opportunity to improve the way people live and communicate. We contribute to human progress by empowering people to express themselves, live in the moment, learn about the world, and have fun together. For more information, visit snap.com. View source

      4/2/25 4:10:00 PM ET
      $SNAP
      Computer Software: Programming Data Processing
      Technology
    • Snap Inc. Announces Fourth Quarter and Full Year 2024 Financial Results

      Fourth quarter revenue increased 14% year-over-year to $1,557 million Daily Active Users increased 9% year-over-year to 453 million Fourth quarter net income of $9 million and Adjusted EBITDA of $276 million Fourth quarter operating cash flow of $231 million and Free Cash Flow of $182 million Snap Inc. (NYSE:SNAP) today announced financial results for the quarter and full year ended December 31, 2024. "In 2024 we made significant progress on our core priorities of growing our community and improving depth of engagement, driving top line revenue growth and diversifying our revenue sources, while building toward our long-term vision for augmented reality," said Evan Spiegel, CEO. "A

      2/4/25 4:10:00 PM ET
      $SNAP
      Computer Software: Programming Data Processing
      Technology

    $SRAX
    $SNAP
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more
    • Snap downgraded by Guggenheim

      Guggenheim downgraded Snap from Buy to Neutral

      2/11/25 7:13:28 AM ET
      $SNAP
      Computer Software: Programming Data Processing
      Technology
    • Barclays reiterated coverage on Snap

      Barclays reiterated coverage of Snap with a rating of Overweight

      2/5/25 8:42:21 AM ET
      $SNAP
      Computer Software: Programming Data Processing
      Technology
    • Snap downgraded by Wells Fargo with a new price target

      Wells Fargo downgraded Snap from Overweight to Equal Weight and set a new price target of $11.00 from $15.00 previously

      2/5/25 7:04:12 AM ET
      $SNAP
      Computer Software: Programming Data Processing
      Technology

    $SRAX
    $SNAP
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more

    $SRAX
    $SNAP
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • Chief Technology Officer Murphy Robert C. gifted 302,084 shares and sold $8,025,400 worth of shares (1,000,000 units at $8.03), decreasing direct ownership by 2% to 54,215,224 units (SEC Form 4)

      4 - Snap Inc (0001564408) (Issuer)

      5/5/25 8:00:03 PM ET
      $SNAP
      Computer Software: Programming Data Processing
      Technology
    • General Counsel O'Sullivan Michael J. sold $185,875 worth of shares (24,000 units at $7.74) (SEC Form 4)

      4 - Snap Inc (0001564408) (Issuer)

      5/1/25 7:00:07 PM ET
      $SNAP
      Computer Software: Programming Data Processing
      Technology
    • General Counsel O'Sullivan Michael J. sold $206,386 worth of shares (24,000 units at $8.60) (SEC Form 4)

      4 - Snap Inc (0001564408) (Issuer)

      4/2/25 7:00:04 PM ET
      $SNAP
      Computer Software: Programming Data Processing
      Technology
    • Miglino Christopher bought $750 worth of SRAX Common Stock (15,000 units at $0.05), increasing direct ownership by 2% to 902,575 units (SEC Form 4)

      4 - SRAX, Inc. (0001538217) (Issuer)

      12/28/23 5:25:44 PM ET
      $SRAX
      Advertising
      Consumer Discretionary

    $SRAX
    $SNAP
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • Snap Inc. Announces First Quarter 2025 Financial Results

      First quarter revenue increased 14% year-over-year to $1,363 million Daily Active Users increased 9% year-over-year to 460 million Net loss improved 54% year-over-year to $140 million Adjusted EBITDA improved 137% year-over-year to $108 million Snap Inc. (NYSE:SNAP) today announced financial results for the quarter ended March 31, 2025. "We surpassed an important milestone in Q1, with our community growing to over 900 million monthly active users," said Evan Spiegel, CEO. "Quarterly revenue increased 14% year-over-year, driven by the progress we have made with our direct-response advertising solutions, continued momentum in driving performance for small and medium sized businesses, and

      4/29/25 4:10:00 PM ET
      $SNAP
      Computer Software: Programming Data Processing
      Technology
    • Snap Inc. Announces Date of First Quarter 2025 Results Conference Call

      Snap Inc. (NYSE:SNAP) will hold its quarterly conference call to discuss first quarter 2025 financial results on Tuesday, April 29, 2025 at 2:00 p.m. Pacific Time (5:00 p.m. Eastern Time). A live webcast and replay of the conference call will be accessible on Snap Inc.'s Investor Relations website for at least 90 days at: http://investor.snap.com. About Snap Inc. Snap Inc. is a technology company. We believe the camera presents the greatest opportunity to improve the way people live and communicate. We contribute to human progress by empowering people to express themselves, live in the moment, learn about the world, and have fun together. For more information, visit snap.com. View source

      4/2/25 4:10:00 PM ET
      $SNAP
      Computer Software: Programming Data Processing
      Technology
    • Later Announces Partnership with Snap Inc. Delivering the Industry's Most Comprehensive Integration for Social and Influencer Marketing

      BOSTON, Feb. 27, 2025 /PRNewswire/ -- Later, a leader in influencer marketing and social media management software and services, today announces a partnership with Snap Inc.  (NYSE:SNAP), that redefines creator partnerships and content publishing on Snapchat. The collaboration introduces two key capabilities through Snapchat's APIs: discovery of creator profiles within Later's influencer marketing platform, and automated content scheduling and posting through Later's social media management platform. Later is the first to integrate both Snapchat's Public Profile API (organic posting) and Creator Discovery API within the same platform.

      2/27/25 9:00:00 AM ET
      $SNAP
      Computer Software: Programming Data Processing
      Technology

    $SRAX
    $SNAP
    FDA approvals

    Live FDA approvals issued by the Food and Drug Administration and FDA breaking news

    See more

    $SRAX
    $SNAP
    SEC Filings

    See more
    • June 7, 2024 - FDA Roundup: June 7, 2024

      For Immediate Release: June 07, 2024 Today, the U.S. Food and Drug Administration is providing an at-a-glance summary of news from around the agency:  Today, the FDA announced that it has advised the manufacturers of the licensed and authorized COVID-19 vaccines that the COVID-19 vaccines (2024-2025 Formula) for use in the United States should be monovalent (single strain) JN.1 vaccines to more closely match cu

      6/7/24 3:46:22 PM ET
      $GERN
      $SRAX
      $SNAP
      Biotechnology: Pharmaceutical Preparations
      Health Care
      Advertising
      Consumer Discretionary
    • March 22, 2024 - FDA Roundup: March 22, 2024

      For Immediate Release: March 22, 2024 Today, the U.S. Food and Drug Administration is providing an at-a-glance summary of news from around the agency:  Today, the FDA issued an emergency use authorization for Pemgarda (pemivibart) for the pre-exposure prophylaxis (prevention) of COVID-19 in certain adults and adolescents (12 years of age and older weighing at least 40 kilograms [about 88 pounds]).  Pemgarda is

      3/22/24 5:02:42 PM ET
      $SNAP
      $SRAX
      Computer Software: Programming Data Processing
      Technology
      Advertising
      Consumer Discretionary
    • November 9, 2023 - FDA Approves First Treatment for Patients with Rare Inherited Blood Clotting Disorder

      For Immediate Release: November 09, 2023 Today, the U.S. Food and Drug Administration approved Adzynma, the first recombinant (genetically engineered) protein product indicated for prophylactic (preventive) or on demand enzyme replacement therapy (ERT) in adult and pediatric patients with congenital thrombotic thrombocytopenic purpura (cTTP), a rare and life-threatening blood clotting disorder. “The FDA remains

      11/9/23 2:30:20 PM ET
      $SRAX
      $SNAP
      Advertising
      Consumer Discretionary
      Computer Software: Programming Data Processing
      Technology
    • SEC Form S-8 filed by Snap Inc.

      S-8 - Snap Inc (0001564408) (Filer)

      5/1/25 4:11:12 PM ET
      $SNAP
      Computer Software: Programming Data Processing
      Technology
    • SEC Form 10-Q filed by SRAX Inc.

      10-Q - SRAX, Inc. (0001538217) (Filer)

      4/30/25 6:18:31 AM ET
      $SRAX
      Advertising
      Consumer Discretionary
    • SEC Form 10-Q filed by Snap Inc.

      10-Q - Snap Inc (0001564408) (Filer)

      4/29/25 7:33:39 PM ET
      $SNAP
      Computer Software: Programming Data Processing
      Technology

    $SRAX
    $SNAP
    Leadership Updates

    Live Leadership Updates

    See more
    • Later Announces Partnership with Snap Inc. Delivering the Industry's Most Comprehensive Integration for Social and Influencer Marketing

      BOSTON, Feb. 27, 2025 /PRNewswire/ -- Later, a leader in influencer marketing and social media management software and services, today announces a partnership with Snap Inc.  (NYSE:SNAP), that redefines creator partnerships and content publishing on Snapchat. The collaboration introduces two key capabilities through Snapchat's APIs: discovery of creator profiles within Later's influencer marketing platform, and automated content scheduling and posting through Later's social media management platform. Later is the first to integrate both Snapchat's Public Profile API (organic posting) and Creator Discovery API within the same platform.

      2/27/25 9:00:00 AM ET
      $SNAP
      Computer Software: Programming Data Processing
      Technology
    • Jim Lanzone Joins Snap Inc. Board of Directors

      Snap Inc. (NYSE:SNAP) announced today that Jim Lanzone, Chief Executive Officer of Yahoo Inc., has been appointed to the company's board of directors, effective as of September 12, 2024. "We are excited to welcome Jim to our board of directors and benefit from his experience in technology and digital advertising," said Evan Spiegel, co-founder and Chief Executive Officer of Snap Inc. "We look forward to working with and learning from him as we continue to grow our business." "Jim's strong technology background will be a key asset for Snap," said Michael Lynton, Chairperson of the board of directors of Snap Inc. "We are glad to have him on the board and I look forward to beginning our work

      9/13/24 4:10:00 PM ET
      $SNAP
      Computer Software: Programming Data Processing
      Technology
    • Xperi Announces Appointment of Two New Independent Directors

      Jeremi Gorman and Roderick Randall Have Expertise in Content Monetization, Digital Media, Automotive Technology and Capital Allocation Board Expands to Seven Directors Xperi Inc. (NYSE:XPER) (the "Company" or "Xperi"), an entertainment technology company that invents, develops and delivers technologies that enable extraordinary experiences, today announced the appointment of Jeremi A. Gorman and Roderick K. ("Rod") Randall to the Board of Directors (the "Board"), effective June 10, 2024. Following the appointment of Ms. Gorman and Mr. Randall, the Board consists of seven directors, six of whom are independent. "We welcome Jeremi and Rod, both accomplished leaders with domain expertise

      6/10/24 4:05:00 PM ET
      $AMZN
      $FSR
      $GAME
      $NFLX
      Catalog/Specialty Distribution
      Consumer Discretionary
      Auto Manufacturing
      Services-Misc. Amusement & Recreation

    $SRAX
    $SNAP
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more
    • SEC Form SC 13G/A filed by SRAX Inc. (Amendment)

      SC 13G/A - SRAX, Inc. (0001538217) (Subject)

      2/14/24 2:56:29 PM ET
      $SRAX
      Advertising
      Consumer Discretionary
    • SEC Form SC 13G/A filed by SRAX Inc. (Amendment)

      SC 13G/A - SRAX, Inc. (0001538217) (Subject)

      2/13/24 7:42:04 PM ET
      $SRAX
      Advertising
      Consumer Discretionary
    • SEC Form SC 13G/A filed by Snap Inc. (Amendment)

      SC 13G/A - Snap Inc (0001564408) (Subject)

      2/13/24 5:14:02 PM ET
      $SNAP
      Computer Software: Programming Data Processing
      Technology